schliessen

Filtern

 

Bibliotheken

Cover Image

Efficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis

Objective. To assess the efficacy and safety of tapentadol IR for moderate to severe pain compared to oxycodone IR. Methods. A search was carried out up to July 2015 for randomized controlled trials (RCTs) of tapentadol IR compared to placebo or oxycodone HCL IR 10 mg for moderate to severe pain. St... Full description

Journal Title: Pain medicine (Malden Mass.), 2017-01-01, Vol.18 (1), p.14-24
Main Author: Xiao, Jing-Ping
Other Authors: Li, Ai-Ling , Feng, Bi-Min , Ye, Yun , Wang, Guo-Jun
Format: Electronic Article Electronic Article
Language: English
Subjects:
Analgesics - therapeutic use
Care and treatment
Comparative analysis
Constipation
Evidence-based medicine
Humans
Meta-analysis
Nausea
Oxycodone
Pain
Pain - drug therapy
Phenols - therapeutic use
Randomized Controlled Trials as Topic
Statistical analysis
Systematic review
Publisher: England: Oxford University Press
ID: ISSN: 1526-2375
Link: https://www.ncbi.nlm.nih.gov/pubmed/27516366
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1859732331
title: Efficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis
format: Article
creator:
  • Xiao, Jing-Ping
  • Li, Ai-Ling
  • Feng, Bi-Min
  • Ye, Yun
  • Wang, Guo-Jun
subjects:
  • Analgesics - therapeutic use
  • Care and treatment
  • Comparative analysis
  • Constipation
  • Evidence-based medicine
  • Humans
  • Meta-analysis
  • Nausea
  • Oxycodone
  • Pain
  • Pain - drug therapy
  • Phenols - therapeutic use
  • Randomized Controlled Trials as Topic
  • Statistical analysis
  • Systematic review
ispartof: Pain medicine (Malden, Mass.), 2017-01-01, Vol.18 (1), p.14-24
description: Objective. To assess the efficacy and safety of tapentadol IR for moderate to severe pain compared to oxycodone IR. Methods. A search was carried out up to July 2015 for randomized controlled trials (RCTs) of tapentadol IR compared to placebo or oxycodone HCL IR 10 mg for moderate to severe pain. Studies were pooled by risk ratio (RR) and weighted mean differences (WMD) with 95% confidence interval (CI). Results. Nine RCTs (n = 3,961) were analyzed. In this meta-analysis, tapentadol IR (50-, 75-, and 100-mg doses) showed significant improvements in moderate to severe pain relief on the sum of pain intensity difference over 48 hours (SPID48) scores (P  0.05) was found. Compared with tapentadol IR 50 mg, tapentadol IR 75 mg demonstrated significant improvement in moderate to severe pain relief based on both SPID48 and TOTPAR48 scores (all P 
language: eng
source:
identifier: ISSN: 1526-2375
fulltext: no_fulltext
issn:
  • 1526-2375
  • 1526-4637
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.4577003
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1859732331
sourceformatXML
sourcesystemPC
galeidA607543402
oup_id10.1093/pm/pnw154
sourcerecordidA607543402
originalsourceidFETCH-LOGICAL-1443t-3049b44cb0ef834f7ecc373bb5703ad13f6f340b5511fa3b14966048ffa80ce20
addsrcrecordideNp9kc1u1DAUhSMEoqWw4AWQJVjAIq0d_yRhF1UFKrUCMcM6unGukaskDrbTKg_BO-PpDCAQQl7Y1_rOuUc6Wfac0VNGa342j2fzdMekeJAdM1moXChePjy8C17Ko-xJCDeUMiUq_jg7KkrJFFfqOPt-YYzVoFcCU082YDCuxBmyhRmnCL0byOU4Ym8hIvmMA0JA0oSAIYwJIHYiW48Q74eku3Y9-h0bHdngLXokn8BOb0lDNmuIOEK0OhndWry7X3mNEfJmgmENNjzNHhkYAj473CfZl3cX2_MP-dXH95fnzVXOhOAx51TUnRC6o2gqLkyJWvOSd50sKYeecaMMF7STkjEDvGOiVoqKyhioqMaCnmSv976zd98WDLEdbdA4DDChW0LLKlmXvOCcJfTlX-iNW3zKm6g6YaoWqvxNfYUBWzsZFz3onWnbKFpKkeLs1p7-g0qnx9FqN6Gx6f8PwZu9QHsXgkfTzt6O4NeW0XZXfTuP7b76xL44BF26VNgv8mfXCXi1B9wy_8fnB5RwtKk
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1985969467
display
typearticle
titleEfficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis
creatorXiao, Jing-Ping ; Li, Ai-Ling ; Feng, Bi-Min ; Ye, Yun ; Wang, Guo-Jun
creatorcontribXiao, Jing-Ping ; Li, Ai-Ling ; Feng, Bi-Min ; Ye, Yun ; Wang, Guo-Jun
descriptionObjective. To assess the efficacy and safety of tapentadol IR for moderate to severe pain compared to oxycodone IR. Methods. A search was carried out up to July 2015 for randomized controlled trials (RCTs) of tapentadol IR compared to placebo or oxycodone HCL IR 10 mg for moderate to severe pain. Studies were pooled by risk ratio (RR) and weighted mean differences (WMD) with 95% confidence interval (CI). Results. Nine RCTs (n = 3,961) were analyzed. In this meta-analysis, tapentadol IR (50-, 75-, and 100-mg doses) showed significant improvements in moderate to severe pain relief on the sum of pain intensity difference over 48 hours (SPID48) scores (P < 0.00001 or P = 0.01). No statistically significant difference among all three doses of tapentadol IR and oxycodone HCL IR 10 mg on both SPID48 and total pain relief over 48 hours (TOTPAR48) scores (all P > 0.05) was found. Compared with tapentadol IR 50 mg, tapentadol IR 75 mg demonstrated significant improvement in moderate to severe pain relief based on both SPID48 and TOTPAR48 scores (all P < 0.05). For total adverse events (AEs) incidence, tapentadol IR 50 and 75 mg were significantly lower than oxycodone HCL IR 10 mg. Incidence of nausea and constipation were significantly lower with either tapentadol IR 50 or 75 mg compared with oxycodone HCL IR 10 mg (all P < 0.05). Conclusions. Tapentadol IR 75 mg might be an optimal dose for moderate to severe pain control with fewer side effects. All three doses of tapentadol IR could provide comparable efficacy to oxycodone HCL IR 10 mg.
identifier
0ISSN: 1526-2375
1EISSN: 1526-4637
2DOI: 10.1093/pm/pnw154
3PMID: 27516366
languageeng
publisherEngland: Oxford University Press
subjectAnalgesics - therapeutic use ; Care and treatment ; Comparative analysis ; Constipation ; Evidence-based medicine ; Humans ; Meta-analysis ; Nausea ; Oxycodone ; Pain ; Pain - drug therapy ; Phenols - therapeutic use ; Randomized Controlled Trials as Topic ; Statistical analysis ; Systematic review
ispartofPain medicine (Malden, Mass.), 2017-01-01, Vol.18 (1), p.14-24
rights
02016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2016
12016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
2COPYRIGHT 2017 American Academy of Pain Medicine
3Copyright © 2016 American Academy of Pain Medicine
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-1443t-3049b44cb0ef834f7ecc373bb5703ad13f6f340b5511fa3b14966048ffa80ce20
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27516366$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Xiao, Jing-Ping
1Li, Ai-Ling
2Feng, Bi-Min
3Ye, Yun
4Wang, Guo-Jun
title
0Efficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis
1Pain medicine (Malden, Mass.)
addtitlePain Med
descriptionObjective. To assess the efficacy and safety of tapentadol IR for moderate to severe pain compared to oxycodone IR. Methods. A search was carried out up to July 2015 for randomized controlled trials (RCTs) of tapentadol IR compared to placebo or oxycodone HCL IR 10 mg for moderate to severe pain. Studies were pooled by risk ratio (RR) and weighted mean differences (WMD) with 95% confidence interval (CI). Results. Nine RCTs (n = 3,961) were analyzed. In this meta-analysis, tapentadol IR (50-, 75-, and 100-mg doses) showed significant improvements in moderate to severe pain relief on the sum of pain intensity difference over 48 hours (SPID48) scores (P < 0.00001 or P = 0.01). No statistically significant difference among all three doses of tapentadol IR and oxycodone HCL IR 10 mg on both SPID48 and total pain relief over 48 hours (TOTPAR48) scores (all P > 0.05) was found. Compared with tapentadol IR 50 mg, tapentadol IR 75 mg demonstrated significant improvement in moderate to severe pain relief based on both SPID48 and TOTPAR48 scores (all P < 0.05). For total adverse events (AEs) incidence, tapentadol IR 50 and 75 mg were significantly lower than oxycodone HCL IR 10 mg. Incidence of nausea and constipation were significantly lower with either tapentadol IR 50 or 75 mg compared with oxycodone HCL IR 10 mg (all P < 0.05). Conclusions. Tapentadol IR 75 mg might be an optimal dose for moderate to severe pain control with fewer side effects. All three doses of tapentadol IR could provide comparable efficacy to oxycodone HCL IR 10 mg.
subject
0Analgesics - therapeutic use
1Care and treatment
2Comparative analysis
3Constipation
4Evidence-based medicine
5Humans
6Meta-analysis
7Nausea
8Oxycodone
9Pain
10Pain - drug therapy
11Phenols - therapeutic use
12Randomized Controlled Trials as Topic
13Statistical analysis
14Systematic review
issn
01526-2375
11526-4637
fulltextfalse
rsrctypearticle
creationdate2017
recordtypearticle
recordideNp9kc1u1DAUhSMEoqWw4AWQJVjAIq0d_yRhF1UFKrUCMcM6unGukaskDrbTKg_BO-PpDCAQQl7Y1_rOuUc6Wfac0VNGa342j2fzdMekeJAdM1moXChePjy8C17Ko-xJCDeUMiUq_jg7KkrJFFfqOPt-YYzVoFcCU082YDCuxBmyhRmnCL0byOU4Ym8hIvmMA0JA0oSAIYwJIHYiW48Q74eku3Y9-h0bHdngLXokn8BOb0lDNmuIOEK0OhndWry7X3mNEfJmgmENNjzNHhkYAj473CfZl3cX2_MP-dXH95fnzVXOhOAx51TUnRC6o2gqLkyJWvOSd50sKYeecaMMF7STkjEDvGOiVoqKyhioqMaCnmSv976zd98WDLEdbdA4DDChW0LLKlmXvOCcJfTlX-iNW3zKm6g6YaoWqvxNfYUBWzsZFz3onWnbKFpKkeLs1p7-g0qnx9FqN6Gx6f8PwZu9QHsXgkfTzt6O4NeW0XZXfTuP7b76xL44BF26VNgv8mfXCXi1B9wy_8fnB5RwtKk
startdate20170101
enddate20170101
creator
0Xiao, Jing-Ping
1Li, Ai-Ling
2Feng, Bi-Min
3Ye, Yun
4Wang, Guo-Jun
generalOxford University Press
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
83V.
97RV
107TK
117X7
127XB
1388E
1488G
158FI
168FJ
178FK
18ABUWG
19AZQEC
20BENPR
21DWQXO
22FYUFA
23GHDGH
24GNUQQ
25K9.
26KB0
27M0S
28M1P
29M2M
30NAPCQ
31PQEST
32PQQKQ
33PQUKI
34PRINS
35Q9U
367X8
sort
creationdate20170101
titleEfficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis
authorXiao, Jing-Ping ; Li, Ai-Ling ; Feng, Bi-Min ; Ye, Yun ; Wang, Guo-Jun
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1443t-3049b44cb0ef834f7ecc373bb5703ad13f6f340b5511fa3b14966048ffa80ce20
rsrctypearticles
prefilterarticles
languageeng
creationdate2017
topic
0Analgesics - therapeutic use
1Care and treatment
2Comparative analysis
3Constipation
4Evidence-based medicine
5Humans
6Meta-analysis
7Nausea
8Oxycodone
9Pain
10Pain - drug therapy
11Phenols - therapeutic use
12Randomized Controlled Trials as Topic
13Statistical analysis
14Systematic review
toplevelpeer_reviewed
creatorcontrib
0Xiao, Jing-Ping
1Li, Ai-Ling
2Feng, Bi-Min
3Ye, Yun
4Wang, Guo-Jun
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7ProQuest Central (Corporate)
8Nursing & Allied Health Database
9Neurosciences Abstracts
10Health & Medical Collection
11ProQuest Central (purchase pre-March 2016)
12Medical Database (Alumni Edition)
13Psychology Database (Alumni)
14Hospital Premium Collection
15Hospital Premium Collection (Alumni Edition)
16ProQuest Central (Alumni) (purchase pre-March 2016)
17ProQuest Central (Alumni Edition)
18ProQuest Central Essentials
19ProQuest Central
20ProQuest Central Korea
21Health Research Premium Collection
22Health Research Premium Collection (Alumni)
23ProQuest Central Student
24ProQuest Health & Medical Complete (Alumni)
25Nursing & Allied Health Database (Alumni Edition)
26Health & Medical Collection (Alumni Edition)
27Medical Database
28Psychology Database
29Nursing & Allied Health Premium
30ProQuest One Academic Eastern Edition
31ProQuest One Academic
32ProQuest One Academic UKI Edition
33ProQuest Central China
34ProQuest Central Basic
35MEDLINE - Academic
jtitlePain medicine (Malden, Mass.)
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Xiao, Jing-Ping
1Li, Ai-Ling
2Feng, Bi-Min
3Ye, Yun
4Wang, Guo-Jun
formatjournal
genrearticle
ristypeJOUR
atitleEfficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis
jtitlePain medicine (Malden, Mass.)
addtitlePain Med
date2017-01-01
risdate2017
volume18
issue1
spage14
epage24
pages14-24
issn1526-2375
eissn1526-4637
abstractObjective. To assess the efficacy and safety of tapentadol IR for moderate to severe pain compared to oxycodone IR. Methods. A search was carried out up to July 2015 for randomized controlled trials (RCTs) of tapentadol IR compared to placebo or oxycodone HCL IR 10 mg for moderate to severe pain. Studies were pooled by risk ratio (RR) and weighted mean differences (WMD) with 95% confidence interval (CI). Results. Nine RCTs (n = 3,961) were analyzed. In this meta-analysis, tapentadol IR (50-, 75-, and 100-mg doses) showed significant improvements in moderate to severe pain relief on the sum of pain intensity difference over 48 hours (SPID48) scores (P < 0.00001 or P = 0.01). No statistically significant difference among all three doses of tapentadol IR and oxycodone HCL IR 10 mg on both SPID48 and total pain relief over 48 hours (TOTPAR48) scores (all P > 0.05) was found. Compared with tapentadol IR 50 mg, tapentadol IR 75 mg demonstrated significant improvement in moderate to severe pain relief based on both SPID48 and TOTPAR48 scores (all P < 0.05). For total adverse events (AEs) incidence, tapentadol IR 50 and 75 mg were significantly lower than oxycodone HCL IR 10 mg. Incidence of nausea and constipation were significantly lower with either tapentadol IR 50 or 75 mg compared with oxycodone HCL IR 10 mg (all P < 0.05). Conclusions. Tapentadol IR 75 mg might be an optimal dose for moderate to severe pain control with fewer side effects. All three doses of tapentadol IR could provide comparable efficacy to oxycodone HCL IR 10 mg.
copEngland
pubOxford University Press
pmid27516366
doi10.1093/pm/pnw154
oafree_for_read